Recently, BEIGENE announced that the U.S. Food and Drug Administration (FDA) has approved Bai Ze An (Tiragolumab) in combination with platinum-based and fluorouracil-based chemotherapy for first-line treatment in adult patients with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer whose tumors express PD-L1 (≥1).
百济神州百泽安在美获批新适应症
BEIGENE's Bai Ze An has been approved for a new indication in the USA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated